Uproleselan

N/A

Report date: 2025/06/19 16:46:47
NME

Base Information

Drug NameUproleselan
Drug Alias NameUproleselan sodiumUproleselan injectionGMI-1271APL-106
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSelectin E inhibitors
TargetsSelectin E
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Myelodysplastic SyndromesVenous Thrombosis +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesCrescent Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesCrescent Biopharma IncWashington University School Of MedicineNational Cancer Institute +[4] 
Inactive CompaniesApollomics IncZhejiang Crownmab Biotech Co LtdApollomics (Hong Kong) Ltd
Active IndicationsMyelodysplastic SyndromesMultiple MyelomaLeukemia, Myeloid, Acute +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Venous ThrombosisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A